Perseus Proteomics Inc.
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Jul 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 13, 2027The maintenance fee for Novel Monoclonal Antibody, and Use Thereof (US 9,155,805) comes due Apr 13, 2027. Unpaid by Oct 13, 2027, it lapses early.
- 1 fee due Oct 9, 2027The maintenance fee for Composition Containing Buffer (US 11,951,168) comes due Oct 9, 2027. Unpaid by Apr 10, 2028, it lapses early.
- 1 fee due Nov 3, 2027The maintenance fee for Anti-CDH3 antibody having high internalization capacity (US 9,328,160) comes due Nov 3, 2027. Unpaid by May 3, 2028, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,388,249 | Method of classifying antibody, method of identifying antigen, method of obtaining antibody or antibody set, method of constructing antibody panel and antibody or antibody set and use of the same In force · From the USPTO record | In force | From the USPTO record | |
| US 9,155,805 | Novel Monoclonal Antibody, and Use Thereof In force · High confidence | In force | High confidence | |
| US 9,328,160 | Anti-CDH3 antibody having high internalization capacity In force · From the USPTO record | In force | From the USPTO record | |
| US 9,764,041 | Drug conjugate comprising anti-CDH3 (P-cadherin) antibody In force · From the USPTO record | In force | From the USPTO record | |
| US 9,598,496 | Antibody capable of specifically recognizing transferrin receptor In force · From the USPTO record | In force | From the USPTO record | |
| US 9,593,165 | Antibody capable of specifically recognizing transferrin receptor In force · From the USPTO record | In force | From the USPTO record | |
| US 9,644,028 | Anti-CDH3 humanized antibody, drug conjugate thereof, and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,030,071 | Antibody which specifically reacts with human integrin A6B4 In force · From the USPTO record | In force | From the USPTO record | |
| US 11,951,168 | Composition Containing Buffer In force · High confidence | In force | High confidence | |
| US 12,752,008 | Composition Containing Buffer In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 11: 3 patents in force now held by others · 14 lapsed for an unpaid fee · 2 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 6 abandoned · 3 no status recorded